Stocks and InvestingStocks and Investing
Thu, July 6, 2023
Wed, July 5, 2023
Mon, July 3, 2023
Fri, June 30, 2023

Graig Suvannavejh Reiterated (BTAI) at Strong Buy and Held Target at $40 on, Jun 30th, 2023


Published on 2024-10-28 04:35:58 - WOPRAI, Graig Suvannavejh
  Print publication without navigation


Graig Suvannavejh of Mizuho, Reiterated "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy and Held Target at $40 on, Jun 30th, 2023.

Graig has made no other calls on BTAI in the last 4 months.



There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 2 agree with Graig's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Decreased Target to $25 on, Friday, May 26th, 2023
  • Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $22 on, Friday, March 10th, 2023


These are the ratings of the 2 analyists that currently disagree with Graig


  • Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $66 on, Tuesday, May 30th, 2023
  • Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $46 on, Tuesday, May 9th, 2023